CNTX
Income statement / Annual
Last year (2025), Context Therapeutics Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Context Therapeutics Inc's net income was -$36.12 M.
See Context Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$31.86 M
|
$22.70 M
|
$17.78 M
|
$7.09 M
|
$3.81 M
|
$1.64 M
|
$2.41 M
|
| General & Administrative Expenses |
$7.85 M
|
$7.22 M
|
$7.29 M
|
$7.79 M
|
$3.63 M
|
$930.67 K
|
$2.97 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$7.85 M
|
$7.22 M
|
$7.29 M
|
$7.79 M
|
$3.63 M
|
$930.67 K
|
$2.97 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$500.00 K
|
$3.09 M
|
$0.00
|
$0.00
|
| Operating Expenses |
$39.70 M
|
$29.92 M
|
$25.07 M
|
$15.38 M
|
$10.53 M
|
$2.57 M
|
$5.38 M
|
| Cost And Expenses |
$39.70 M
|
$29.92 M
|
$25.07 M
|
$15.38 M
|
$10.53 M
|
$2.57 M
|
$5.38 M
|
| Interest Income |
$3.38 M
|
$3.20 M
|
$1.16 M
|
$547.27 K
|
$64.24
|
$661.22
|
$1.10 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$547.27 K
|
$64.24 K
|
$661.22 K
|
$1.10 M
|
| Depreciation & Amortization |
$16.25 K
|
$10.88 K
|
$12.04 K
|
$9.27 K
|
$0.00
|
$0.00
|
$0.00
|
| EBITDA |
-$39.69 M |
-$29.91 M |
-$25.06 M |
-$14.87 M |
-$10.39 M |
-$2.57 M |
-$5.38 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$3.58 M
|
$3.20 M
|
$1.11 M
|
$545.26 K
|
$68.95 K
|
$9.22 M
|
-$1.01 M
|
| Income Before Tax |
-$36.12 M
|
-$26.73 M
|
-$23.96 M
|
-$14.84 M
|
-$10.46 M
|
$6.64 M
|
-$6.38 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$36.12 M
|
-$26.73 M
|
-$23.96 M
|
-$14.84 M
|
-$10.46 M
|
$6.64 M
|
-$6.38 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.38 |
-0.46 |
-1.5 |
-0.93 |
-3.69 |
0.61 |
-0.68 |
| EPS Diluted |
-0.38 |
-0.46 |
-1.5 |
-0.93 |
-3.69 |
-0.8 |
-0.68 |
| Weighted Average Shares Out |
$95.19 M
|
$58.42 M
|
$15.97 M
|
$15.97 M
|
$2.83 M
|
$10.96 M
|
$10.96 M
|
| Weighted Average Shares Out Diluted |
$95.19 M
|
$58.42 M
|
$15.97 M
|
$15.97 M
|
$2.83 M
|
$10.96 M
|
$10.96 M
|
| Link |
|
|
|
|
|
|
|
